pravastatin has been researched along with Focal Segmental Glomerulosclerosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quiroz, Y; RodrÃguez-Iturbe, B; Sato, T; Vaziri, ND | 1 |
| Hattori, M; Ito, K; Kawaguchi, H; Khono, M; Kubota, R; Tanaka, T | 1 |
| Li, J; Lu, Y; Zheng, X | 1 |
3 other study(ies) available for pravastatin and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cholesterol, VLDL; Drug Therapy, Combination; Glomerulosclerosis, Focal Segmental; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Imidazoles; Male; Olmesartan Medoxomil; Pravastatin; Proteinuria; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Renal Insufficiency; Tetrazoles; Triglycerides | 2004 |
Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis.
Topics: Adolescent; Blood Component Removal; Combined Modality Therapy; Drug Resistance; Glomerulosclerosis, Focal Segmental; Humans; Hyperlipidemias; Immunosuppressive Agents; Kidney Function Tests; Lipoproteins, LDL; Male; Nephrotic Syndrome; Pravastatin | 1993 |
[Lipid-lowering effect of pravastatin on glomerulosclerosis protection and treatment].
Topics: Animals; Anticholesteremic Agents; Cholesterol; Glomerulosclerosis, Focal Segmental; Male; Nephrotic Syndrome; Pravastatin; Puromycin; Rats; Rats, Sprague-Dawley; Triglycerides | 1997 |